Clinical trial
The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients
NCT02044692 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients
- Lead sponsor
- Green Cross Corporation
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- January 31, 2014
- Completion date
- January 31, 2020
- Enrollment
- 34 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
hunter syndrome